Join the club for FREE to access the whole archive and other member benefits.

Oisin Biotechnologies

Drug development company focused on the senolytic technology to fight age-related diseases

Oisin Biotechnologies is a platform drug development company focused on creating drugs to combat a variety of age related diseases.

When cells detect that they have been irreversibly damaged, they enter a non-dividing condition known as cell-cycle arrest, or senescence. It’s believed this occurs to prevent cells from going rogue and turning cancerous. Ideally, they should die by the process known as apoptosis, but as we age, more and more frequently they don’t. They become zombie cells – unable to kill themselves or resume normal function.

Senescent cells secrete molecules that cause inflammation in an effort to attract immune cells that would usually clear them. But for reasons that are not fully known, as we age, persistently senescent cells accumulate, leading to a vast number of age-related diseases.

Visit website:

 Login to view link, or join the club to get full access to all resources and other benefits.

Oisin Biotechnologies is also referenced in the following:


Quick summary of SENS’ latest research projects and other activities

People at Oisin Biotechnologies

Company Representative

Founder and Chief Executive Officer at Oisín Biotechnologies


CSO Oision Biotechnologies, co-founder of Oisin Oncology and Chair in Prostate Cancer Research at the University of Alberta

Oisin Biotechnologies News

Longevity Technology interviews Aubrey de Grey about senolytics and other senotherapeutics

Longevity Technology - 05-Aug-2021

Most approaches have their limitations but good progress is being made on several fronts


Oisín raised $9.5M to advance senolytic therapies for kidney & age-related diseases

Longevity Technology - 28-May-2021

Investigational therapy on old mice cleared senescent cells up to 70%, extending life by 20%


LMC provides background and success outlook on 14 leading senolytic companies

Longevity Marketcap - 15-Dec-2020

Comprehensive review of companies' clinical and financial state of play


Nature Biotechnology reviews the state of play of senolytics

Nature Biotechnology - 12-Nov-2020

In August, Unity announced that its lead drug candidate had failed to beat a placebo in reducing ...


OncoSenX raises more funds for cancer therapy, plans for clinical trial

GeekWire - 11-May-2020

Allowing developments on tech that will kill cancer based on their genetics


Fight Aging! reports back from SENS Research Foundation Pitch Day

Fight Aging! - 20-Jan-2020

When some of these succeed in human trials even more money will pile in to fund further advances


OncoSenX targets solid tumours with senolytics (LEAF) - 22-Oct-2019

Phase 1 clinical trial starting early 2020


SRF has made progress in the fight against ageing (LEAF) - 05-Dec-2017

R&D phase in SENS repair approach has shown promising results


False Positives in Senescent Cell Detection (LEAF) - 19-Aug-2017

Researchers commonly determine the presence of senescent cells through the use of the p16ink4a (p...


Hallmark of Aging Reversed by Senescent Cell Removal (LEAF) - 25-Mar-2017

Study directly targets one of the mechanisms that senescent cells use to avoid apoptosis, Focuse...


A Look at Ascendance Biomedical, Packaging Medical Tourism for Longevity Therapies

Fight Aging! - 28-Dec-2016

It is focused on the twofold path of (a) establishing patient-funded trials of potentially usefu...


Fight Aging predicts the sequence of arrival for meaningful antiaging therapies

Next Big Future - 01-Dec-2016

Each treatment will target a different type of molecular damage in cells and tissues. 1) Clearan...